NDC 50090-1007

REYATAZ

Atazanavir

REYATAZ is a Oral Capsule, Gelatin Coated in the Human Prescription Drug category. It is labeled and distributed by A-s Medication Solutions. The primary component is Atazanavir Sulfate.

Product ID50090-1007_07a92e16-603b-4208-88e9-ed3399a3c3e6
NDC50090-1007
Product TypeHuman Prescription Drug
Proprietary NameREYATAZ
Generic NameAtazanavir
Dosage FormCapsule, Gelatin Coated
Route of AdministrationORAL
Marketing Start Date2003-06-24
Marketing CategoryNDA / NDA
Application NumberNDA021567
Labeler NameA-S Medication Solutions
Substance NameATAZANAVIR SULFATE
Active Ingredient Strength300 mg/1
Pharm ClassesHIV Protease Inhibitors [MoA],Protease Inhibitor [EPC],UGT1A1 Inhibitors [MoA],UDP Glucuronosyltransferases Inhibitors [MoA],Cytochrome P450 3A4 Inhibitors [MoA],Cytochrome P450 3A Inhibitors [MoA],Cytochrome P450 2C8 Inhibitors [MoA]
NDC Exclude FlagN
Listing Certified Through2019-12-31

Packaging

NDC 50090-1007-0

30 CAPSULE, GELATIN COATED in 1 BOTTLE, PLASTIC (50090-1007-0)
Marketing Start Date2014-11-28
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 50090-1007-0 [50090100700]

REYATAZ CAPSULE, GELATIN COATED
Marketing CategoryNDA
Application NumberNDA021567
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2014-11-28
Marketing End Date2017-11-30

Drug Details

Active Ingredients

IngredientStrength
ATAZANAVIR SULFATE300 mg/1

OpenFDA Data

SPL SET ID:c217bd23-a05a-4ba6-a86c-8e98db206adb
Manufacturer
UNII
RxNorm Concept Unique ID - RxCUI
  • 402093
  • 664741
  • 402247
  • 664743

    • Pharmacological Class

    • HIV Protease Inhibitors [MoA]
    • Protease Inhibitor [EPC]
    • UGT1A1 Inhibitors [MoA]
    • UDP Glucuronosyltransferases Inhibitors [MoA]
    • Cytochrome P450 3A4 Inhibitors [MoA]
    • Cytochrome P450 3A Inhibitors [MoA]
    • Cytochrome P450 2C8 Inhibitors [MoA]

    NDC Crossover Matching brand name "REYATAZ" or generic name "Atazanavir"

    NDCBrand NameGeneric Name
    0003-3622REYATAZATAZANAVIR
    0003-3624REYATAZATAZANAVIR
    0003-3631REYATAZATAZANAVIR
    0003-3638REYATAZATAZANAVIR
    50090-1007REYATAZATAZANAVIR
    50090-1581REYATAZATAZANAVIR
    69189-3631REYATAZREYATAZ
    69189-3624REYATAZREYATAZ
    70518-0725REYATAZREYATAZ
    70518-0688REYATAZREYATAZ
    70518-0469REYATAZREYATAZ
    67296-1236REYATAZREYATAZ
    31722-653AtazanavirAtazanavir
    31722-654AtazanavirAtazanavir
    31722-655AtazanavirAtazanavir
    42385-920AtazanavirAtazanavir
    42385-921AtazanavirAtazanavir
    42385-922AtazanavirAtazanavir
    59762-0408ATAZANAVIRATAZANAVIR
    59762-0409ATAZANAVIRATAZANAVIR
    59762-0410ATAZANAVIRATAZANAVIR
    0904-6875Atazanavir SulfateAtazanavir
    16714-860Atazanavir SulfateAtazanavir
    16714-861Atazanavir SulfateAtazanavir
    16714-862Atazanavir SulfateAtazanavir
    60687-399Atazanavir SulfateAtazanavir
    65862-710Atazanavir SulfateAtazanavir
    65862-711Atazanavir SulfateAtazanavir

    Trademark Results [REYATAZ]

    Mark Image

    Registration | Serial
    Company
    Trademark
    Application Date
    REYATAZ
    REYATAZ
    78804555 not registered Dead/Abandoned
    Bristol-Myers Squibb Company
    2006-02-01
    REYATAZ
    REYATAZ
    78169764 not registered Dead/Abandoned
    Bristol-Myers Squibb Company
    2002-10-01
    REYATAZ
    REYATAZ
    78169761 not registered Dead/Abandoned
    Bristol-Myers Squibb Company
    2002-10-01
    REYATAZ
    REYATAZ
    78169757 not registered Dead/Abandoned
    Bristol-Myers Squibb Company
    2002-10-01
    REYATAZ
    REYATAZ
    78169754 not registered Dead/Abandoned
    Bristol-Myers Squibb Company
    2002-10-01
    REYATAZ
    REYATAZ
    78131406 2846482 Live/Registered
    Bristol-Myers Squibb Company
    2002-05-28
    REYATAZ
    REYATAZ
    77829869 4415058 Live/Registered
    Bristol-Myers Squibb Company
    2009-09-18
    © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.